Abstract

Background Multicentric Castleman Disease (MCD) is an idiopathic lymphoproliferative disorder, exceptionally reported in children, probably due to an increase of interleukin 6 secretion. MCD is characterized by systemic lymphadenopathy and constitutional inflammatory symptoms including severe growth retardation. Previous studies in adult showed that anti-interleukin 6 receptor antibody alleviated symptoms and biochemical abnormalities of MCD.

Highlights

  • Multicentric Castleman Disease (MCD) is an idiopathic lymphoproliferative disorder, exceptionally reported in children, probably due to an increase of interleukin 6 secretion

  • Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab

  • Previous studies in adult showed that anti-interleukin 6 receptor antibody alleviated symptoms and biochemical abnormalities of MCD

Read more

Summary

Background

Multicentric Castleman Disease (MCD) is an idiopathic lymphoproliferative disorder, exceptionally reported in children, probably due to an increase of interleukin 6 secretion. MCD is characterized by systemic lymphadenopathy and constitutional inflammatory symptoms including severe growth retardation. Previous studies in adult showed that anti-interleukin 6 receptor antibody alleviated symptoms and biochemical abnormalities of MCD. Months for the first patient who had sustained remission since 3 years. The second patient is treated every two weeks since 8 months

Conclusions
Methods
Results

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.